Alnylam Pharmaceuticals and Celldex Therapeutics are among the biotech companies in Massachusetts that received tax credits as part of a $1 billion program included in the health reform law. "The program helps biotech companies continue to discover new cures and therapies to solve unmet medical needs, while adding good jobs across the Commonwealth," said Robert K. Coughlin, the Massachusetts Biotechnology Council's president and CEO.

Related Summaries